Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in Advanced Biliary Tract Cancer
NCT03473574Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- May 2018
- Primary completion
- Mar 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in cholangiocarcinoma (CCA), gallbladder carcinoma, sponsored by AIO-Studien. Started May 2018; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
cholangiocarcinoma (CCA)gallbladder carcinoma
Beyond the preview
Go deeper on NCT03473574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03473574.